Home > Insider Trading > Filing (0001104659-22-103846)

Filing Details

Accession Number:: 0001104659-22-103846
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-09-29 06:08:35
Reporting Period:: 2022-09-28

Accepted Time:: 2022-09-29 06:08:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1740279	In8Bio Inc.	INAB	Biological Products, (No Disgnostic Substances) (2836)	825462585

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1813270	Cavu Management, Lp	C/O Bios Equity Partners 1751 River Run Suite 400 Fort Worth TX 76107	Yes	No	Yes	No
1813310	Cavu Advisors, Llc	C/O Bios Equity Partners 1751 River Run Suite 400 Fort Worth TX 76107	Yes	No	Yes	No
1813313	Bios Equity Partners Ii, Lp	C/O Bios Equity Partners 1751 River Run Suite 400 Fort Worth TX 76107	Yes	No	Yes	No
1813316	W. Leslie Kreis	C/O Bios Equity Partners 1751 River Run Suite 400 Fort Worth TX 76107	Yes	No	Yes	No
1831976	Bios Equity Partners Iii, Lp	C/O Bios Equity Partners 1751 River Run Suite 400 Fort Worth TX 76107	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-09-28	3,070	$2.02	592,766	No	5	P	Indirect	See footnote
Common Stock	Acquisiton	2022-09-28	19,017	$2.02	3,670,545	No	5	P	Indirect	See footnote
Common Stock	Acquisiton	2022-09-28	2,913	$2.02	561,989	No	5	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	5	P	Indirect	See footnote
No	5	P	Indirect	See footnote
No	5	P	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	574,432	Indirect	See footnote
Common Stock	1,876,624	Indirect	See footnote
Common Stock	251,211	Indirect	See footnote
Common Stock	997,433	Indirect	See footnote

Footnotes

Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and BIOS Incysus Co-Invest I, LP ("BIOS Incysus"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Bios Capital Management, LP ("Bios Management") and Cavu Management, LP ("Cavu Management") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management. Cavu Advisors LLC ("Cavu Advisors") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr.
Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
The securities are directly held by Bios Fund III NT.
The securities are directly held by Bios Fund III QP.
The securities are directly held by Bios Fund III.
The securities are directly held by Bios Fund II.
The securities are directly held by Bios Fund II QP.
The securities are directly held by Bios Fund II NT.
The securities are directly held by BIOS Incysus.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 1.73 to $2.15, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4.